🔎 Trials Near Me

Home › Acute Myeloid Leukemia › Maryland

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Maryland

31 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa Maryland.

Mga Lungsod sa Maryland

Opisyal na teksto ng pag-aaral (English)

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06904066

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
  • at 10 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Walter Reed National Military Medical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Center for Cancer and Blood Disorders, Bethesda
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05564390

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06398457

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Walter Reed National Military Medical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05554406

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

  • Johns Hopkins University, Baltimore
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06284486

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • at 1 pa
Nagre-recruitPhase 3
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • John Hopkins School of Medicine, Baltimore
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06824168

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Edad 12 hanggang 120 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05436418

Longitudinal Studies of Patient With FPDMM

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
1 Day – 100 Years · Lahat ng kasarian · Na-update Set 11, 2026 · NCT03854318

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

  • The Center for Cancer and Blood Disorders, Bethesda
Nagre-recruitObservasyonal na pag-aaral
Edad 0 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Baltimore MD-UMGCCC, Baltimore
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Baltimore MD-UMGCCC, Baltimore
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • University of Maryland/Greenebaum Cancer Center, Baltimore
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

  • Tania Jain, MD, Baltimore
Nagre-recruitPhase 1
6 Months – 80 Years · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT02203903

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT05588154

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
1 Day – 120 Years · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT05350748

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • University of Maryland Medical Center (UMMC), Baltimore
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Johns Hopkins, Baltimore
  • Nih/Niaid, Bethesda
  • Nih/Nhlbi, Bethesda
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitObservasyonal na pag-aaral
1 Month – 120 Years · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT07019155

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT04050280

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  • The Center for Cancer and Blood Disorders (CCBD), Bethesda
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT04068597

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Sibley Memorial Hospital, Baltimore
  • University of Maryland, Baltimore
  • Johns Hopkins Main Center, Baltimore
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Johns Hopkins School of Medicine, Baltimore
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • Johns Hopkins University, Baltimore
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Hul 25, 2025 · NCT05237258

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.